ReviewClinics in liver disease2017
Evolution of Experimental Models of the Liver to Predict Human Drug Hepatotoxicity and Efficacy.
Review in Clinics in liver disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 51 citations in OpenAlex.
- Dietary, Nutrient, and Supramolecular Nanofiber Modulation of the Liver Sinusoidal Clearance System in Metabolic Diseases and Aging.Biomedicines · 2026Review
- BiGraph-DTA: Predicting drug-target interactions of hepatoprotective agents with graph convolutional networks.Quantitative biology (Beijing, China) · 2026Article
- Scaling human liver microphysiological systems: implementing a higher-throughput liver acinus microphysiological system platform.Experimental biology and medicine (Maywood, N.J.) · 2026Article
- Vitrification and rapid rewarming of precision-cut liver slices for pharmacological and biomedical research.Bioengineering & translational medicine · 2026Article
- Integrated Patient Digital and Biomimetic Twins for Precision Medicine: A Perspective.Seminars in liver disease · 2025Review
- Targeted cellular depletion in an immune-liver-on-a-chip platform elucidates cell-type-specific heterogeneity in drug-induced hepatotoxicity.Communications biology · 2025Article
- Article
- Microfluidic gut-axis-on-a-chip models for pharmacokinetic-based disease models.Biomicrofluidics · 2024Review
- In Vitro Hepatotoxicity of Routinely Used Opioids and Sedative Drugs.Current issues in molecular biology · 2024Article
- Comparison of wild-type and high-risk PNPLA3 variants in a human biomimetic liver microphysiology system for metabolic dysfunction-associated steatotic liver disease precision therapy.Frontiers in cell and developmental biology · 2024Article
- Synthesis, Computational, and Anticancer In Vitro Investigations of Aminobenzylnaphthols Derived from 2-Naphtol, Benzaldehydes, and α-Aminoacids via the Betti Reaction.Molecules (Basel, Switzerland) · 2023Article
- Review
- Article
- Generation of a Transgenic Zebrafish Line for In Vivo Assessment of Hepatic Apoptosis.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Evaluation of Human Liver Microtissues for Drug Screening onACS infectious diseases · 2021Article
- Human biomimetic liver microphysiology systems in drug development and precision medicine.Nature reviews. Gastroenterology & hepatology · 2021Review
- A Critical Perspective on 3D Liver Models for Drug Metabolism and Toxicology Studies.Frontiers in cell and developmental biology · 2021Review
- Use of Zebrafish in Drug Discovery Toxicology.Chemical research in toxicology · 2020Review
- Improving natural product research translation: From source to clinical trial.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2020Article
- A cell lines derived microfluidic liver model for investigation of hepatotoxicity induced by drug-drug interaction.Biomicrofluidics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
In this article, we review the past applications of in vitro models in identifying human hepatotoxins and then focus on the use of multiscale experimental models in drug development, including the use of zebrafish and human cell-based, 3-dimensional, microfluidic systems of liver functions as key components in applying Quantitative Systems Pharmacology (QSP). We have implemented QSP as a platform to improve the rate of success in the process of drug discovery and development of therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.